anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a method and a device for determining an interested area in a pathological image, computer equipment and a computer readable storage medium. The method comprises the following steps: the pathology image is segmented to obtain a plurality of sub-regions. At least one association region for each sub-region is obtained, wherein the association region partially coincides with the sub-region. Inputting the sub-region and the associated region into a classification model to obtain a confidence that the sub-region is a region of interest. And determining the region of interest in the pathological image based on the confidence degree of the sub-region as the region of interest and a preset threshold value. According to the scheme of the invention, on one hand, the film reading efficiency and the accuracy of the film reading are improved, and on the other hand, the accuracy and the speed of determining whether the sub-region is the region of interest are also improved.
Interactive sexual risk intervention and didactic safer injection education: In each city, 75 women will participate in the 60 minute "Di No Al Sexo Inseguro" \[Say No to Unsafe Sex'\] counseling session. This one on one intervention incorporates elements of MI and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of unsafe sex and condom use with clients. In addition, participants will be provided a lecture format presentation on safer injection sharing. However, in this component, there will be no theory-driven active skill building elements oriented towards safer injection behavior.
The Centers for Disease Control and Prevention recommend that HIV infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV. 

Emtricitabine: Samples of breast milk obtained from five HIV-1 infected mothers show that emtricitabine is secreted in human milk. Breastfeeding infants whose mothers are being treated with emtricitabine may be at risk for developing viral resistance to emtricitabine. Other emtricitabine-associated risks in infants breastfed by mothers being treated with emtricitabine are unknown.

Rilpivirine: Studies in lactating rats and their offspring indicate that rilpivirine was present in rat milk. It is not known whether rilpivirine is secreted in human milk.

Tenofovir Disoproxil Fumarate: Samples of breast milk obtained from five HIV-1 infected mothers in the first post-partum week show that tenofovir is excreted in human milk. The impact of this exposure in breastfed infants is unknown.

Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed if they are receiving COMPLERA.
UNLABELLED: The aim of this study was to assess the relationship of different chronic diseases with immunonutritional markers in the senior population.
METHODS: this study included 1190 hospitalized geriatric patients. The criteria to participate were ability to communicate, given consent and C-reactive protein (CRP) lower than 6 mg/dL.
RESULTS: the mean age of the study population was 81.7 ± 7.6 years. NLR (neutrophil-to-lymphocyte ratio), LMR (lymphocyte-to-monocyte ratio), MWR (monocyte-to-white blood cell ratio), SII (systemic immune-inflammation index), PNI (prognostic nutritional index) and CAR (C-reactive protein-to-albumin ratio) were related to age. NLR and MWR were higher, while LMR, PLR (platelet-to-lymphocyte ratio and SII were lower in men. All markers were related to BMI. NLR, LMR, LCR (lymphocyte-to-CRP ratio), MWR, PNI and CAR were related to several concomitant chronic diseases. In multivariate analyses, age and BMI were selected as independent predictors of all studied immunonutritional markers. Atrial fibrillation, diabetes mellitus and dementia appear most often in the models. PNI presented the most consistent statistical association with age, BMI and concomitant chronic diseases.
CONCLUSIONS: this study reveals the pivotal role of aging and BMI in inflammatory marker levels and the association of immunonutritional markers with different chronic diseases. Atrial fibrillation seems to have the most dominant connection to the immunonutritional markers.
The present invention pertains to a filler composition comprising β- glucan moieties and optionally a cosmetically and/or pharmaceutically acceptable carrier. It further relates to a filler composition, wherein said β-glucan moieties are cross-linked. In one embodiment of the instant invention the filler composition is a dermal filler. In one further embodiment of the present invention the filler composition is for the treatment of wrinkles and/or folds. In another embodiment of the instant invention the filler composition is for use in the treatment of a medical condition. The filler composition provided in the present invention may further comprise one or more active pharmaceutical ingredients. Further, the present invention pertains to a process for preparing the filler composition as claimed herein.
In Arm 3 (single intervention 2- plant-based food provision only), participants will be given plant-based meals from Village FREEdge (up to two meals per day with a maximum of two meals per pick-up) only and will have no classes. Although these participant will not be provided a food prescription as part of the food prescription program the plant-based meals that Village FREEdge will have available to the community members as part of their community service will be the exact same plant-based meals provided through the food prescription program.These subjects will be asked to complete one survey and a nutrition knowledge test at the beginning of the study, one survey every 3 months thereafter and one additional nutrition test 1 year into the study.
Patients assigned to group A will be sampled for a total of 3 consecutive FNA passes with a sequential method of "standard suction", "slow-pull", and "wet suction". After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence.
The invention provides persimmon vinegar with a life prolonging effect. Mature and fresh persimmons serve as principal raw materials. Auxiliary materials of the persimmon vinegar comprise the following traditional Chinese medicines in part by weight: 20 parts of ginseng, 10 parts of cartialgenous, 10 parts of prepared rehmannia roots, 5 parts of white atractylodes rhizome, 5 parts of astragalus membranaceus, 25 parts of Chinese-dates, 10 parts of roots of red-rooted salvia, 20 parts of groundnut kernels and 25 parts of hawthorn. The mature and fresh persimmons and the auxiliary materials are jointly fermented into the persimmon vinegar; and the ratio of the weight of the mature and fresh persimmons to the total weight of the traditional Chinese medicines is 100:1-15. The persimmon vinegar has effects of improving impurity, regulating internal secretion, regulating angiocarpy, cultivating life and preserving health. Moreover, the persimmon vinegar with the life prolonging effect has the advantages that the persimmon vinegar tastes sour and sweet, has a reddish bright color and mild Chinese medicine smell and does not have toxic or side effects, people can eat the persimmon vinegar when having dinner and can also eat the persimmon vinegar independently, and effects of benefiting qi and nourishing blood and promoting blood circulation to remove blood stasis are high.
Antibody light chain amyloidosis is a disorder in which protein aggregates, mainly composed of immunoglobulin light chains, deposit in diverse tissues impairing the correct functioning of organs. Interestingly, due to the high susceptibility of antibodies to mutations, AL amyloidosis appears to be strongly patient-specific. Indeed, every patient will display their own mutations that will make the proteins involved prone to aggregation thus hindering the study of this disease on a wide scale. In this framework, determining the molecular mechanisms that drive the aggregation could pave the way to the development of patient-specific therapeutics. Here, we focus on a particular patient-derived light chain, which has been experimentally characterized. We investigated the early phases of the aggregation pathway through extensive full-atom molecular dynamics simulations, highlighting a structural rearrangement and the exposure of two hydrophobic regions in the aggregation-prone species. Next, we moved to consider the pathological dimerization process through docking and molecular dynamics simulations, proposing a dimeric structure as a candidate pathological first assembly. Overall, our results shed light on the first phases of the aggregation pathway for a light chain at an atomic level detail, offering new structural insights into the corresponding aggregation process.
The present invention relates to the fields of medicine and in particular cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cells, in particular cancer cells, or changing the immunopeptidome, in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a therapy in a subject in need thereof. The invention also discloses methods for treating a disease, in particular cancer, for preventing or treating cancer metastasis and/or cancer recurrence, in a subject. The present invention in addition provides kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.
CONTEXT: Patients with chronic obstructive pulmonary disease (COPD) experience pain as both symptom and comorbidity. There has been no evaluation of the recommendations for pain management in updated clinical practice guidelines (CPGs).
OBJECTIVES: Update the evidence on pain management, determine alignment of pain management recommendations with best-practice, and advocate for optimal pain management in patients with COPD.
METHODS: PubMed, Guideline International Network, Guideline Portal, Agency for Healthcare Research and Quality, National Institute for Healthcare Excellence, Scottish International Guidelines Network, Institute of Medicine, grey literature, national websites, and bibliographies were searched. CPGs available online for stable COPD produced by organizations representing reputable knowledge of COPD management were included. CPGs unavailable online, not translatable into English, or not including techniques within the defined scope were excluded. Researchers performed frequency counts for the verbatim terms "pain," "physical activity," "exercise," "rehabilitation," "physical therap(ist)/(y), "physiotherap(ist)/(y)," recorded context, and collected recommendations for pain management/treatment when present.
RESULTS: Of 32 CPGs, 24 included "pain" verbatim. Of these, 13 included recommendations for pain treatment/management. Common recommendations included opioids, pharmacological management, further medical assessment, and surgical intervention. Two CPGs referred to palliative care, one CPG discussed treating cough, and one discussed massage, relaxation, and breathing.
CONCLUSIONS: Pain management recommendations vary and are not aligned with evidence. Pain should be addressed in patients with COPD, whether directly or indirectly related to the disease. Reduction of variability in pain management and the disease burden is necessary. Pain management should include referrals to providers who can maximize benefit of their services.
PURPOSE: To provide a food composition, intraintestinal control agent or pharmaceutical, in each of which a TGF(transforming growth factor)-β-like MGF(milk growth factor) derived from milk or colostrum of a mammal is used and each of which is effective in treating intestinal inflammatory disease or a transplant-host reaction. CONSTITUTION: In this composition, milk-derived polypeptides (growth factors) of the TGF-β- family are used for the control of immune response mediated by an MHC (major histocompatibility complex) of a mammal gastrointestinal tract, in particular, treatment of intestinal inflammatory disease (such as Crohn disease or large-intestinal ulcer) or a human or animal transplant-host reaction, prevention of a human or animal weaning brash and prevention of an allergy reaction in a human or animal gastrointestinal tract. It is recently confirmed that an MGF that is one of these growth factors used, is the same as a member of the TGF-β-family, specifically, the TGF-[32, or has close homology with the TGF-β2.  The TGF-β are homodimer proteins each of which has an about 25kDa molecular weight and consists of the same two polypeptide chains each having about 12.5kDa molecular weight, wherein the two polypeptide chains are joined together by disulfide-crosslinking. Also, each of these proteins can be joined to another protein to form a latent protein complex. Each of the complexes thus formed can be activated by acid treatment or mild protein decomposition.
PURPOSE: Fetal movements are crucial indicators of fetal well-being, with reduced fetal movements (RFM) suggesting potential fetal compromise. Fetal growth restriction (FGR), often linked to placental insufficiency, is a major cause of perinatal morbidity and mortality. This study aimed to investigate the neonatal, labor, and placental outcomes of FGR pregnancies with and without RFM at term.
METHODS: In this retrospective study, data from all term, singleton deliveries with FGR and concomitant RFM were obtained and compared to an equal control group of FGR without RFM. Maternal characteristics, pregnancy and neonatal outcomes, and placental histology were compared. The primary outcome was a composite of adverse neonatal outcomes. A multivariable regression analysis was performed to identify independent associations with adverse neonatal outcomes.
RESULTS: During the study period, 250 FGR neonates with concomitant RFM and an equal control group were identified. The groups did not differ in maternal demographics aside from significantly higher rates of maternal smoking in the RFM group (p < 0.001). Polyhydramnios and oligohydramnios (p = 0.032 and p = 0.007, respectively) and meconium-stained amniotic fluid (p < 0.001) were more prevalent in the FGR+RFM group. Additionally, the RFM group showed higher rates of adverse neonatal outcomes despite having larger neonates (p = 0.047 and p < 0.001, respectively). No significant differences were observed in placental findings. Logistic regression identified RFM as an independent predictor of adverse neonatal outcomes (aOR 2.45, 95% CI 1.27-4.73, p = 0.008).
CONCLUSION: Reduced fetal movements are significant and independent predictors of worse neonatal outcomes in FGR pregnancies, suggesting an additional acute insult on top of underlying placental insufficiency.
The control group will be a retrospective cohort taken from 1-year before the implementation of the LDCT surveillance program. The post-operative follow-up of these participants was not standardized, but rather left up to the discretion of the individual surgeons, and involved chest radiograph imaging as opposed to Low Dose Computed Tomography.
The patients allocated to the control group will have access to an online booklet containing general information about self-management of chronic pain, including pain education, advice on healthy lifestyle and sleeping habits and promotion of exercises. They will also receive one phone call at week 4 and text messages once a week during the study period.
VIVID is a prospective, multicenter, randomized clinical trial that will evaluate three specific research questions. In black patients eligible for a primary prevention implantable cardioverter defibrillator (ICD), 1) what is the effect of a patient-centered educational video compared with usual care (UC) on knowledge of SCD (Sudden Cardiac Death), associated risk factors, and ICDs; 2) what is the effect of a patient-centered educational video compared with UC on the decision for ICD implantation, decisional conflict, and receipt of an ICD within 90 days; 3) what is the effect of racial concordance between study patients and video participants (health care providers/patients) on the decision for ICD implantation, decisional conflict and ICD receipt within 90 days. In addition, in-depth qualitative interviews (IQI) with a sample of trial participants will be conducted to determine the salient influences on their decision and explore the reasons for their ultimate decision and subsequent implantation or non-implantation of an ICD.

Approximately 480 patients eligible for a primary prevention ICD will be enrolled at approximately 12 hospitals in this study. Study sites selected for VIVID will be geographically diverse and provide care to a significant proportion of racial and ethnic minority patients. Patient's will be mailed a letter regarding the study, prior to their initial visit. At the initial visit, patients will be approached about participation in the trial. For those interested, informed consent will be obtained and patients will be randomized. The investigators will be utilizing electronic consents on an iPad. Black patients will be randomized to one of 3 arms: educational videos presented in the same format; one with black participants (patients and providers) or the other with white participants (patients and providers); The third arm will be usual care (control) and the provider can interact with the patient consistent with their typical/usual care. Notably, for both intervention and control arms, all patient management decisions are completely at the discretion of the care providers.
Background: Clinical studies have shown that the onset and exacerbation of chronic obstructive pulmonary disease (COPD) are related to obesity and dietary behaviours, but the genetic relationship between them is not clear.Aims: To investigate the relationship between the genetic determinants of obesity, dietary habits (alcohol consumption, intake of sweets, salt intake) and COPD.Methods: Exposure and outcome datasets were obtained from the IEU Open GWAS project. The exposure dataset includes dietary habits (Salt added to food, Sweets intake, Alcohol consumption), obesity level (represented by body mass index (BMI) and body fat percentage (BFP) data sets.). The outcome dataset includes COPD and acute COPD admissions. The collected data were imported into the RStudio software and conducted Mendelian randomisation analysis. Additionally, heterogeneity and horizontal pleiotropy tests were conducted on the data to ensure the veracity of the results.Results: The results showed that BMI was positively correlated with the risk of acute COPD admission (OR = 1.74, 95% CI 1.39-2.18) and COPD (OR = 1.81, 95%CI 1.41-2.33). In addition, BFP was also a risk factor for COPD (OR = 1.98, 95% CI 1.42-2.77) and acute exacerbation of COPD admission (OR = 1.99, 95%CI 1.43-2.77). The increase of salt, sugar and alcohol consumption will not increase the risk of COPD and the risk of hospitalisation due to COPD.Conclusion: Therefore, we should strengthen the guidance of diet and living habits of obese patients. For patients with heavier weight and higher body fat rate, they should be instructed to lose weight and fat to prevent the occurrence of COPD. For obese patients with COPD, more attention should be paid to prevent the occurrence of acute exacerbation of COPD in advance.
Cook Like A Boss Online is a virtual cooking camp styled intervention, providing engaging virtual cooking activities for children to take part in safely from their homes during the COVID-19 pandemic. The online intervention is adapted from the original theory-driven, age-appropriate and co-created 'Cook Like A Boss' intervention (Dean et al., 2022), into daily cooking videos emailed to parents for children to cook along to, aiming to improve perceived cooking competence and wellbeing. Children aged 9-12 years will be recruited from across the island of Ireland (Republic of Ireland and Northern Ireland) to take part in the intervention. Due to the uncertainty of the pandemic and the need for the intervention to run five days consecutively (i.e. over a school holiday), it is deemed unethical to have a delayed intervention control group and all children will be provided the opportunity to take part in the intervention. Study outcomes include perceived cooking competence, perceived motor competence, wellbeing and process evaluation measures and will be collected at baseline and post intervention.
Sepsis is a systemic inflammatory response that requires effective macrophage metabolic functions to resolve ongoing inflammation. Previous work showed that the mechanosensitive cation channel, transient receptor potential vanilloid 4 (TRPV4), mediates macrophage phagocytosis and cytokine production in response to lung infection. Here, we show that TRPV4 regulates glycolysis in a stiffness-dependent manner by augmenting macrophage glucose uptake by GLUT1. In addition, TRPV4 is required for LPS-induced phagolysosome maturation in a GLUT1-dependent manner. In a cecal slurry mouse model of sepsis, TRPV4 regulates sepsis-induced glycolysis as measured by BAL fluid (BALF) lactate and sepsis-induced lung injury as measured by BALF total protein and lung compliance. TRPV4 is necessary for bacterial clearance in the peritoneum to limit sepsis-induced lung injury. It is interesting that BALF lactate is increased in patients with sepsis compared with healthy control participants, supporting the relevance of lung cell glycolysis to human sepsis. These data show that macrophage TRPV4 is required for glucose uptake through GLUT1 for effective phagolysosome maturation to limit sepsis-induced lung injury. Our work presents TRPV4 as a potential target to protect the lung from injury in sepsis.
The invention concerns novel cationic polymers of formula (I) in which n is a whole number between 0 and 5 and p is a whole number between 2 and 20000, more particularly p ranges between 10 and 18000, and advantageously between 200 and 1000, characterised in that: at least 10 %, advantageously 30 to 80 %, preferably 70 %, of the free NH¿2? functions are substituted by identical or different hydrophilic R groups; said cationic polymer can further comprise at least a targeting element associated covalently or not with the free NH¿2? functions and/or said hydrophilic R groups provided that said cationic polymer contains at least 20 %, preferably at least 30 %, of free NH¿2? functions. The invention also concerns a complex comprising at least said cationic polymer associated with at least a therapeutically active substance, in particular a nucleic acid comprising at least a negative charge. The invention is useful for transferring a nucleic acid into target cells, in particular for gene therapy.
Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment.